EP4456886A1 — Phenylephrine premix formulations and uses thereof
Assigned to Baxter Healthcare SA · Expires 2024-11-06 · 2y expired
What this patent protects
The present disclosure is directed to a pharmaceutical premix phenylephrine formulation comprising phenylephrine hydrochloride and a salt, e.g., sodium chloride, where the formulation has a pH from about 3.0 to 6.5. Also presented is a system containing an oxygen scavenger, a pho…
USPTO Abstract
The present disclosure is directed to a pharmaceutical premix phenylephrine formulation comprising phenylephrine hydrochloride and a salt, e.g., sodium chloride, where the formulation has a pH from about 3.0 to 6.5. Also presented is a system containing an oxygen scavenger, a photosensitive overpouch, and a pharmaceutical premix phenylephrine formulation. Methods of treating hypotension, e.g., resulting primarily from vasodilation, in such settings as septic shock or anaesthesia, in a human subject are also described.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.